MedTech Actuator is thrilled to celebrate a significant achievement by alumnus, Eldin Rostom. Eldin, the visionary CEO and Founder of Diag-Nose.io, has earned a place on the Forbes 30 Under 30 Asia list for Healthcare & Science in 2024. This accolade recognises Eldin’s groundbreaking work in revolutionising respiratory care with cutting-edge AI-powered technology.

Breathing New Life into Respiratory Care

At the heart of Diag-Nose.io’s innovation is their flagship product, RhinoMAP. This AI-driven tool leverages protein signatures to expedite the diagnosis process for patients with chronic respiratory conditions, enabling them to receive the right treatment faster. With over 500 million people worldwide affected by chronic respiratory disorders, the impact of RhinoMAP is profound.

“Our mission is to improve a billion lives globally,” Eldin says. “RhinoMAP is designed to overcome the lengthy diagnosis process and help patients breathe better and live longer.”

From Patient to Pioneer

Eldin’s journey in healthcare innovation is as personal as it is professional. Born with a rare disease (Toxoplasmosis), Eldin spent much of his early life in and out of hospitals. This firsthand experience with the challenges of healthcare ignited his passion for using technology to improve patient outcomes.

“Being an asthma patient myself, I found immense joy and pride in being able to work towards a world free of respiratory disorders,” Eldin shares. This personal connection to his work drives the relentless pursuit of his vision at Diag-Nose.io.

MedTech Actuator: A Launchpad for Success

Eldin’s path to success was significantly shaped by his participation in MedTech Actuator Origin in 2019. The program provided him with critical insights into medtech commercialisation, regulatory landscapes, and intellectual property—essential knowledge for any medtech entrepreneur.

“MedTech Actuator Origin gave us the conviction to continue on with the startup journey,” Eldin reflects. “We met some pretty amazing mentors, friends, and advisors through the program that are still part of our journey to this day.”

Looking Ahead

Joining the Forbes 30 Under 30 Asia 2024 cohort has already begun to open new doors for Diag-Nose.io, attracting interest from investors and the media. Eldin hopes this recognition will lead to more collaborations and partnerships, enabling the company to scale its impact and reach even more patients in need.

As Eldin and his team continue to push the boundaries of respiratory care, they exemplify the spirit of innovation and perseverance that MedTech Actuator aims to foster. Their success is not only a source of inspiration for aspiring healthcare entrepreneurs but also a powerful reminder of how technology can transform patient lives.

Apply for MedTech Actuator Origin 2024

Are you driven to change the face of healthcare like Eldin? Applications are open for MedTech Actuator Origin 2024 until Monday, August 26.

Whether you’re a researcher, scientist, clinician or student, MedTech Actuator Origin is looking for passionate entrepreneurs poised to transform healthcare. The winner of MedTech Actuator Origin will receive a $15k cash and in-kind prize pack and gain access to fast-tracked entry into MedTech Actuator Accelerator 2025.

Have questions about the application or program? Reach out to Lizzie Laurence, Program Coordinator via email – lizzie@medtechactuator.com

MedTech Actuator Origin is supported by LaunchVic.